Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
about
Therapies targeting cancer stem cells: Current trends and future challengesOvarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?CD133, Selectively Targeting the Root of CancerCancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cellsGastric cancer stem cells: evidence, potential markers, and clinical implications.Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancerCD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer.Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant SettingRecent technological advances in using mouse models to study ovarian cancer.Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.A bispecific EpCAM/CD133-targeted toxin is effective against carcinomaTargeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance.Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment.Bioinformatic prediction and experimental validation of a PE38-based recombinant immunotoxin targeting the Fn14 receptor in cancer cells.Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling.Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker.Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.Synergy of Dendritic Cell Vaccines and Avasimibe in Treatment of Head and Neck Cancer in Mice.Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC.Stemness-Related Markers in Cancer.Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC.Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance.
P2860
Q26777880-C8EFD260-0226-4E7E-B8BE-04E9A1B6A93DQ26826899-74B7D0A1-73F4-4D42-B603-B06761B18080Q28066353-1FC3ED70-B980-4F2C-AAAD-4F2361D88B7DQ35507539-334C5869-EC2E-451C-8F2F-C001A4C3B40EQ35795934-11DBCD85-9325-4CC4-8815-64E936C54CD1Q36293646-A24DF970-037C-4861-A797-4F75DF825F49Q36406924-DB4CCF11-D39C-4189-BF6B-31F42B00C5EAQ37180487-F7384A46-7385-4830-9F53-F431CF7CD3DDQ37581537-0D4D4430-ECD3-40AB-B4FA-51DCD837D9F8Q38266427-3E7F8A1B-1347-4183-B39F-0FE9DE381B28Q38819645-F48E40F6-B2B7-465F-8069-C91DB879181CQ38867217-E917A90B-302C-4629-A056-7EDCEDA6AB78Q38937280-AE110049-E965-45A5-8291-10390E9AD1C2Q39177087-67727416-540A-4BE8-B7A9-B6181BC73BA0Q40267233-18662F6B-83A3-4FF9-8096-59CB51B877C2Q41083994-BE20CE21-5BBB-4BC8-8B18-9F1179E5BA82Q42221543-6C147DBC-0215-4F14-B469-F6D414DD1E3DQ42317503-32A51B0F-8E14-44FC-A464-AA29AA0DA114Q42364245-E566839F-A2D3-45B6-9756-A7B2FBB70A33Q42425463-9A97F1E1-D435-403E-BC6D-E7BE4443C708Q47176774-3CA0A657-95AB-4203-A83D-7A2D68E0CC3EQ50027358-C0BEF766-5423-4B6D-96D2-8E7C9BAC34BCQ50053655-243C08B5-AA29-4093-BFD1-74A2153348E1Q50992976-6BBEDEB7-204B-430D-82B2-B1A8FCE6F9F7Q53697399-48489226-E73A-455A-BDFE-F1CAA42F633D
P2860
Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
@en
Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
@nl
type
label
Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
@en
Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
@nl
prefLabel
Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
@en
Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
@nl
P2093
P2860
P1433
P1476
Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
@en
P2093
Amy P N Skubitz
Daniel A Vallera
Elizabeth P Taras
Kristin L M Boylan
Nate N Waldron
Seunguk Oh
P2860
P304
P356
10.1016/J.YGYNO.2013.05.027
P407
P577
2013-05-27T00:00:00Z